<DOC>
	<DOCNO>NCT01216046</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety VX-809 VX-770 alone combination healthy subject .</brief_summary>
	<brief_title>Drug-Drug Interaction Study VX-770 VX-809 Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , multiple-dose study orally administer VX-809 VX-770 healthy subject . This study evaluate safety tolerability VX-809 VX-770 alone combination . Subjects randomize receive study drug placebo three 14-day treatment period separate 14-day washout period . In Treatment Period 1 , subject randomize study drug receive VX-809 every 24 hour . In Treatment Period 2 , subject randomize study drug receive VX-770 every 12 hour . In Treatment Period 3 , subject receive VX-809 every 24 hour VX-770 every 12 hour . Subjects randomize placebo receive placebo treatment period . Enrollment plan 1 clinical site ( Lenexa , Kansas ) . Up 72 subject enrol . The study separate 3 dose escalation cohort . Cohort 1 Cohort 2 enroll 24 subject . Cohort 3 optional may conduct review safety pharmacokinetic data Vertex .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive Body mass index ( BMI ) 18.5 30.0 kg/m2 , inclusive Subjects child bear potential sexually active must meet contraception requirement Female subject must negative serum pregnancy test screen Day 1 History illness , opinion investigator might confound result study pose additional risk administer study drug subject Participated clinical study involve administration either investigational marketed drug within 30 day 5 terminal halflives ( whichever longer ) Screening visit Subject receive VX770 VX809 previous clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>